Compare · DXCM vs XAIR
DXCM vs XAIR
Side-by-side comparison of DexCom Inc. (DXCM) and Beyond Air Inc. (XAIR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and XAIR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 5679.9x XAIR ($5.2M).
- Over the past year, DXCM is down 10.6% and XAIR is down 88.9% - DXCM leads by 78.3 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 2 for XAIR).
- DXCM has more recent analyst coverage (25 ratings vs 5 for XAIR).
- Company
- DexCom Inc.
- Beyond Air Inc.
- Price
- $76.59+5.15%
- $0.41+2.69%
- Market cap
- $29.57B
- $5.2M
- 1M return
- +25.71%
- -17.42%
- 1Y return
- -10.56%
- -88.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 2
- Recent ratings
- 25
- 5
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Beyond Air Inc.
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest XAIR
- Beyond Air Inc. filed SEC Form 8-K: Other Events
- Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
- Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.
- SEC Form DEF 14A filed by Beyond Air Inc.
- SEC Form PRE 14A filed by Beyond Air Inc.
- Beyond Air Inc. filed SEC Form 8-K: Other Events
- Beyond Air to Participate in the D. Boral Capital Global Conference 2026
- Beyond Air Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Beyond Air Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure